KRAS Alleles: The Devil Is in the Detail.
KRAS Alleles: The Devil Is in the Detail.
复制标题
DOI：
10.1016/j.trecan.2017.08.006
复制
发表时间：
2017-10
期刊：
影响因子：
18.4
通讯作者：
Haigis KM
中科院分区：
文献类型：
--
作者：
Haigis KM
KRAS是癌症中最常发生突变的癌基因，KRAS突变通常与不良预后和对治疗的耐药性相关。由于KRAS癌蛋白目前还不能直接作为药物靶点，针对KRAS突变癌症的努力集中在识别下游信号通路或应激反应通路中的薄弱环节，这些环节允许强烈的致癌信号传导。KRAS生物学中一个未被充分认识的方面是许多不同的KRAS激活突变之间潜在的生物学差异。本综述借鉴临床和实验研究的见解，探讨KRAS等位基因之间的相似性和差异性。历史和新出现的证据支持这样一种观点，即与每个等位基因相关的特定生物学特性可能可用于等位基因特异性治疗。
KRAS is the most frequently mutated oncogene in cancer and KRAS mutation is commonly associated with poor prognosis and resistance to therapy. Since the KRAS oncoprotein is, as yet, not directly druggable, efforts to target KRAS mutant cancers focus on identifying vulnerabilities in downstream signaling pathway or in stress-response pathways that are permissive for strong oncogenic signaling. One aspect of KRAS biology that is not well appreciated is the potential biological differences between the many distinct KRAS activating mutations. This review draws upon insights from both clinical and experimental studies to explore similarities and differences among KRAS alleles. Historical and emerging evidence supports the notion that the specific biology related to each allele might be exploitable for allele-specific therapy.
登录
查看更多内容
影响因子：
64.5
作者：
Burgess MR;Hwang E;Mroue R;Bielski CM;Wandler AM;Huang BJ;Firestone AJ;Young A;Lacap JA;Crocker L;Asthana S;Davis EM;Xu J;Akagi K;Le Beau MM;Li Q;Haley B;Stokoe D;Sampath D;Taylor BS;Evangelista M;Shannon K
通讯作者：
Shannon K
影响因子：
3.6
作者：
Bournet B;Muscari F;Buscail C;Assenat E;Barthet M;Hammel P;Selves J;Guimbaud R;Cordelier P;Buscail L
通讯作者：
Buscail L
影响因子：
45.3
作者：
Eberhard, DA;Johnson, BE;Hillan, KJ
通讯作者：
Hillan, KJ
影响因子：
64.5
作者：
DER, CJ;FINKEL, T;COOPER, GM
通讯作者：
COOPER, GM
影响因子：
30.8
作者：
Haigis, Kevin M.;Kendall, Krystle R.;Jacks, Tyler
通讯作者：
Jacks, Tyler